**Editorial**

**Title: concisely convey the main topic(s) of the research**

[***Suggestions: No more than 16 words. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.***]

**Forename Surname1, Forename Surname1,2, Forename Surname3**

1Department, Institution, City Postcode, Country.

2Department, Institution, City, State Postcode, Country.

3Department, Institution, City Postcode, Province, Country.

**Correspondence to:** Prof./Dr. Forename Surname, Department, Institution, Detailed Address, City Postcode, Country. E-mail: [xxxx@xxxx.xxx](mailto:xxxx@xxxx.xxx); ORCID: xxxx

**Received: date month year**

[e.g.,1 Jan 2025]

**How to Use This Template**

***This template shows the manuscript structure that can be used in an editorial: Main Text, Declarations and References. Please note that each part has a corresponding style, which authors should follow. Please note that the fonts in gray show writing requirements. For any questions, you may contact the [editorial office](mailto:xxxx@.com).***

**LEVEL 1 HEADING**

[e.g.,**MAIN TEXT**]

In this section, authors should describe the main text of the manuscript in detail. If necessary, we suggest that authors may set headings (level 1 heading, level 2 heading, level 3 heading, *etc.*) to separate different cases or situations.

**Level 2 heading**

*Level 3 heading*

* ***All drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration, should be identified precisely.***

**Table 1** (other forms: Tables 1 and 2; Tables 1-3),**Equation (1)** [other forms: Equations (2) and (3); Equations (4-6)] and **Figure 1** (other forms: Figure 1A and B; Figure 2A-C; Figures 1 and 2A; Figures 1, 2A and 3-5) show the examples of diagrams. All the tables, equations and figures should be cited in sequence in the main content near to the first time they appear. For supplementary material, authors may cite table, equation and figure like **Supplementary Table 1**, **Supplementary Equation (1)** and **Supplementary Figure 1**. For details, you may refer to **[Supplementary Material Template](https://oaepublish.com/files/tpl/imc/Template_for_Supplementary_Material_imc.docx)**.

***Tips:***

* ***Results should be presented in a logical sequence;***
* ***Avoid redundant explanations to all the data from the tables or illustrations.***

**Table 1. This is a table caption. A summary description of this table should be written here**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Authors** | **Regimen** | ***n*** | **Age (year)** | **CR (%)** | **2-year (3-year) EFS/PFS (%)** | **2-year (3-year) OS (%)** |
| Our current study | CHOP CVP | 251 67 | 17-82 45-87 | 69.8 29.9\* | 55.3 (46.0) 18.0 (12.0)\* | 58.0 (52.0) 25.0 (19.0)\* |
| Khaled *et al.*[1] | CHOP | 40 | 19-75 | 67 | 54 (54) | 82 (71) |
| Burton *et al.*[2] | CHOP CIOP | 105 106 | 22-66 25-67 | 70 52 | 4-year PFS: 56 4-year PFS: 40\* | 4-year OS: 65 4-year OS: 56# |

This part is footer. \**P* < 0.05, #*P* ≥ 0.05. EFS: event-free survival; PFS: progression-free survival; OS: overall survival; CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP: cyclophosphamide, vincristine, and prednisone; CIOP: cyclophosphamide, idarubicin, vincristine, and prednisone; CR: complete response. This table is cited with permission from Li *et al*.[1] published in xxx.

***Table notes:***

* ***Tables should be cited in numeric order and placed after the paragraph where it is first cited;***
* ***The table caption should be placed above the table and labeled sequentially (e.g., Table 1, Table 2);***
* ***Tables should be provided in editable form like DOC or DOCX format (picture is not allowed);***
* ***Abbreviations and symbols used in table should be explained in footnote;***
* ***Explanatory matter should also be placed in footnotes;***
* ***Non-English words should be avoided;***
* ***Permission for use of copyrighted materials from other sources, including re-published, adapted, modified, or partial tables from the internet, must be obtained. It is authors’ responsibility to acquire the licenses, to follow any citation instruction requested by third-party rights holders, and cover any supplementary charges.***

|  |  |
| --- | --- |
| **A** | 图二  **B** |
| **C** | |

**Figure 1.** We present examples of electron micrograph, non-editable and editable images in Figure 1A-C. A: description of what the Figure 1A is; B: description of what the Figure 1B is; C: description of what the Figure 1C is. This figure is quoted with permission from XX *et al*.[2]

***Figure notes:***

* ***Figures should be cited in numeric order (e.g., Figure 1, Figure 2) and placed after the paragraph where it is first cited;***
* ***Figures can be submitted in format of tiff, psd, AI or jpeg, with resolution of 300-600 dpi;***
* ***Diagrams with describing words (including, flow chart, coordinate diagram, bar chart, line chart, and scatter diagram, etc.) should be editable in word, excel or powerpoint format. Non-English information should be avoided;***
* ***Labels, numbers, letters, arrows, and symbols in figure should be clear, of uniform size, and contrast with the background;***
* ***Symbols, arrows, numbers, or letters used to identify parts of the illustrations must be identified and explained in the legend;***
* ***Internal scale (magnification) should be explained and the staining method in photomicrographs should be identified;***
* ***All non-standard abbreviations should be explained in the legend;***
* ***Authors should pay attention to the protection of patients’ rights, such as privacy and portrait, and obtain signed patient consent from authors before using any personal information of patients. The patient’s portrait with full characters and his/her real name is not allowed for use;***
* ***Permission for use of copyrighted materials from other sources, including re-published, adapted, modified, or partial figures and images from the internet, must be obtained. It is authors’ responsibility to acquire the licenses, to follow any citation instruction requested by third-party rights holders, and cover any supplementary charges.***

|  |  |
| --- | --- |
|  | (1) |

***Equation note:***

* ***Equations should be provided in editable form (image file format is not allowed).***

**DECLARATIONS**

**Acknowledgments**

Anyone who contributed towards the article but does not meet **[the criteria](http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html)** for authorship, including those who provided professional writing services or materials, should be acknowledged. Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgments section. This section is not added if the author does not have anyone to acknowledge.

**Authors’ contributions**

Single author:

The author contributed solely to the article.

Two or more authors:

Made substantial contributions to conception and design of the study and performed data analysis and interpretation: Salas H, Castaneda WV;

Performed data acquisition, as well as provided administrative, technical, and material support: Castillo N, Young V

**Availability of data and materials**

Not applicable.

**Financial support and sponsorship**

If there are sources of funding for the study reported, any relevant grant numbers and the link of funder’s website should be provided if any. The role of the funding body in the experiment design, collection, analysis and interpretation of data, and writing of the manuscript should be declared:

This work was supported by Grant name XX (No. XXXX; No. XXX)...

If there is no grant:

None.

**Conflicts of interest**

If there are any potential conflicts of interest that may be perceived as inappropriately influencing the representation or interpretation of reported research results, please declare here.

If not, please write as “All authors declared that there are no conflicts of interest.”.

Some authors may be bound by confidentiality agreements. In such cases, in place of itemized disclosures, we will require authors to state “All authors declare that they are bound by confidentiality agreements that prevent them from disclosing their conflicts of interest in this work.”.

If authors are unsure whether conflicts of interest exist, please refer to the “Conflicts of Interest” in the **[Editorial Policies](https://chesynjournal.com/pages/view/editorial_policies)** of *Intelligent Materials & Catalysis* for a full explanation.

**Ethical approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Copyright**

© The Author(s) 2025.

**REFERENCES**

Authors should cite references in sequence throughout the manuscript and indicate them in a superscript square bracket with one citation number[3], two separate citation numbers[4,5] or several consecutive citation numbers[6-9].

* ***We suggest that authors should cite appropriate, traceable and latest references be within recent 5 years;***
* ***Each reference should have a corresponding DOI number/website link;***
* ***If there are six authors or less, please list all the authors; If there are more than six authors, please list the first three authors with et al.;***
* ***The names of journals should be abbreviated according to the style used in Index Medicus (*<http://www2.bg.am.poznan.pl/czasopisma/medicus.php?lang=eng>*)****.* ***The names of journals should be Italic.***

Examples of references are shown below:

**Journal articles by individual authors**

Weaver, D. L.; Ashikaga, T.; Krag, D. N. Effect of occult metastases on survival in node-negative breast cancer. *N. Engl. J. Med.* **2011**, *364*, 412-421. DOI: 10.1056/NEJMoa1008108

**Organization as author**

Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. *Hypertension* **2002**, *40*, 679-686. DOI: 10.1161/01.HYP.0000035706.28494.09

**Both personal authors and organization as author**

Vallancien, G.; Emberton, M.; Harving, N.; van Moorselaar, R. J.; Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms*. J. Urol.***2003**, *169*, 2257-2261. DOI: 10.1097/01.ju.0000067940.76090.73

**Journal articles not in English**

Zhang X.; Xiong H.; Ji T. Y.; Zhang Y. H.; Wang Y. Case report of anti-N-methyl-D-aspartate receptor encephalitis in child. *J. Appl. Clin. Pediatr.* **2012**, *27*, 1903-1907. (in Chinese)

**Journal articles ahead of print**

Odibo, A. O. Falling stillbirth and neonatal mortality rates in twin gestation: not a reason for complacency. *BJOG*. **2018**, Epub ahead of print [DOI: 10.1111/1471-0528.15541]

**ebook**

Hammond, C. *The Basics of Crystallography and Diffraction*, 4th ed.; Oxford University Press, 2015. DOI: 10.1093/acprof:oso/9780198738671.001.0001

**Book in print**

Frankel, F. *Picturing Science and Engineering*; MIT Press, 2018.

**ebook chapter**

Hammond, C. Crystal Symmetry. In *The Basics of Crystallography and Diffraction*, 4th ed.; International Union of Crystallography Texts on Crystallography, Vol. 21; Oxford University Press, 2015; pp 99−134. DOI: 10.1093/acprof:oso/9780198738671.003.0004

**ebook with editors**

*Mom the Chemistry Professor: Personal Accounts and Advice from Chemistry Professors Who Are Mothers*, 2nd ed.; Woznack, K., Charlebois, A., Cole, R. S., Marzabadi, C. H., Webster, G., Eds.; Springer, 2018. DOI: 10.1007/978-3-319-78972-9

**ebook series**

Gaede, H. C. Professional Development for REU Students. In *Best Practices for Chemistry REU Programs*; Griep, M. A, Watkins, L., Eds.; ACS Symposium Series, Vol. 1295; American Chemical Society, 2018; pp 33−44. DOI: 10.1021/bk-2018-1295.ch003

**Thesis or dissertation**

Cable, M. L. Life in Extreme Environments: Lanthanide-Based Detection of Bacterial Spores and Other Sensor Design Pursuits. Ph.D. Dissertation, California Institute of Technology, Pasadena, CA, 2010. http://resolver.caltech.edu/CaltechTHESIS:05102010-145436548 (accessed 2019-09-10).

**Thesis or dissertation in print**

Enander, R. T. Lead particulate and methylene chloride risks in automotive refinishing. Ph.D. Thesis, Tufts University, Medford, MA, 2001.

**Website**

*World Health Organization Home Page*. https://www.who.int/ (accessed 2019-02-21).

**Newspaper**

Beauge, J. School district sued over burns girl suffered during chemistry class demonstration. *PennLive (Harrisburg, PA)*, November 17, 2018, updated November 17, 2018. https://www.pennlive.com/news/2018/11/school\_district\_sued\_over\_burn.html (accessed 2019-02-22).

**Conference abstract**

Okita, J.; Iwamoto, T.; Kira, M. Novel synthetic route for hydrosilyllithiums. In *Book of Abstracts, 2000 International Chemical Congress of Pacific Basin Societies (PACIFICHEM 2000)*, Honolulu, HI; Paper INOR 216.

**Conference proceedings**

Nilsson, A.; Petersson, F.; Persson, H. W.; Jönsson, H.; Laurell, T. Manipulation of suspended particles in a laminar flow. In *Micro Total Analysis Systems 2002, Proceedings of the μTAS 2002 Symposium*, Nara, Japan, November 3−7, 2002; Baba, Y., Shoji, S., van den Berg, A., Eds.; Kluwer Academic Publishers: Dordrecht, The Netherlands, 2002; Vol. 2, pp 751−753. DOI: 10.1007/978-94-010-0504-3\_50

**Database**

*SpectraBase*. Bio-Rad Laboratories. https://spectrabase.com/ (accessed 2020-01-05).

**Patent**

Stern, M. K.; Cheng, B. K. M. Process for preparing N-(p-nitroaryl)amides via reaction of nitrobenzene with nitriles. US 5380946, 1995.

**Preprint**

Yamamoto T. S.; Inui R.; Tada Y.; Yokoyama S. Prospects of detection of subsolar mass primordial black hole and white dwarf binary mergers. *arXiv* **2004**, arXiv:2401.00044. Available online: https://arxiv.org/abs/2401.00044 (accessed 29 December 2023).